Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Innovations and highlights in the Pharma industry 

Dive deep into the world of Pharma with Zamann’s Expert Blog. Our industry-leading professionals share insights on global project management, quality consultancy, digitalization, and more. Stay updated with trends and innovations transforming the Pharma industry. 

News and more

Cipla Licence Cancellation Withdrawn; Bombay HC Challenges Maharashtra FDA Procedure

The Maharashtra Food and Drugs Administration has withdrawn its cancellation of drug sale licences for Cipla Pharma & Life Sciences Ltd’s carrying and forwarding facility in Wadki, Pune, after the Bombay High Court criticised the procedure behind the action. The
  • News
Cipla Licence Cancellation Withdrawn; Bombay HC Challenges Maharashtra FDA Procedure

Best LabWare LIMS Alternatives in 2026: Features, Pricing, Validation, and Pharma Compliance Compared

Compare leading LIMS platforms for regulated pharmaceutical laboratories and see how they differ in validation, compliance, audit trails, deployment, and workflow control. This guide helps quality and laboratory teams choose a system that better fits operational and regulatory needs.
  • Blog, Computerized System Validation
Pharmaceutical laboratory using LIMS software with data integrity, audit trail, and GxP compliance controls.

Baxter Saline Recall Flags Fiberglass Risk; Particulate Controls Face New Scrutiny

Baxter International has voluntarily recalled two lots of 0.9% Sodium Chloride Injection in the United States because of the potential presence of fiberglass particulate matter. The FDA published Baxter’s announcement on August 26, 2026. The affected 500 mL VIAFLEX products
  • News
Baxter Saline Recall Flags Fiberglass Risk; Particulate Controls Face New Scrutiny

Apitegromab Met Its Trial Goal; Manufacturing Issues Forced Scholar Rock’s EU Reset

Scholar Rock has withdrawn its European application for apitegromab, its experimental spinal muscular atrophy treatment, and plans to resubmit using a different manufacturing site. The decision follows manufacturing compliance, fill-finish facility, and regulatory path issues at the Bloomington, Indiana site
  • News
Apitegromab Met Its Trial Goal; Manufacturing Issues Forced Scholar Rock’s EU Reset

No Quality Defect, Yet EU Supply Is Disrupted: EMA Flags Paliperidone Shortage

The European Medicines Agency has reported a shortage of long-acting injectable paliperidone palmitate medicines in some EU member states after manufacturing problems at Greek contract manufacturer Pharmathen International disrupted supply. The affected medicines treat adults with schizophrenia whose condition has
  • News
No Quality Defect, Yet EU Supply Is Disrupted: EMA Flags Paliperidone Shortage

Boston Scientific Cyberattack Hits Orders; Global Operations Disrupted as Recovery Begins

Boston Scientific said a cybersecurity incident detected on August 25 disrupted global operations, including information systems used to process and ship customer orders. The medical-device manufacturer activated incident-response procedures and began working with third-party cybersecurity specialists. Disruptions are expected to
  • News
Boston Scientific Cyberattack Hits Orders; Global Operations Disrupted as Recovery Begins

Pharma Engineering Consultants in 2026: Facility Design, CQV, GMP Utilities, and Project Delivery

Successful pharmaceutical facilities depend on smart design, reliable utilities, qualified equipment, and strong engineering controls. This guide explains how specialist consultants support GMP-ready projects, reduce compliance risks, strengthen CQV activities, and improve facility performance from design through handover.
  • Blog, Validation and Qualification
Engineers reviewing pharmaceutical facility design, process engineering, and clean utilities inside a modern GMP manufacturing facility.

FDA Returns to Cipla Pithampur;7 Observations Renew GMP Remediation Pressure

USFDA issued a Form 483 with seven inspectional observations to Cipla Limited’s Pithampur manufacturing facility in Madhya Pradesh after a follow-up cGMP inspection from August 17 to August 25, 2026. The outcome renews scrutiny of a site that received eight
  • News
FDA Returns to Cipla Pithampur;7 Observations Renew GMP Remediation Pressure